Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas

por Li, Tommy, Hiemstra, Ida H., Chiu, Christopher, Oliveri, Roberto S., Elliott, Brian, DeMarco, Dena, Salcedo, Theodora, Egerod, Frederikke Lihme, Sasser, Kate, Ahmadi, Tahamtan, Gupta, Manish
Publicado 2022

Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment

por Clemens, Pamela L., Yan, Xiaoyu, Lokhorst, Henk M., Lonial, Sagar, Losic, Nedjad, Khan, Imran, Jansson, Richard, Ahmadi, Tahamtan, Lantz, Kristen, Zhou, Honghui, Puchalski, Thomas, Xu, Xu Steven
Publicado 2016

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond

por van de Donk, Niels W. C. J., Janmaat, Maarten L., Mutis, Tuna, Lammerts van Bueren, Jeroen J., Ahmadi, Tahamtan, Sasser, A. Kate, Lokhorst, Henk M., Parren, Paul W. H. I.
Publicado 2016

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma

por Yan, Xiaoyu, Clemens, Pamela L., Puchalski, Thomas, Lonial, Sagar, Lokhorst, Henk, Voorhees, Peter M., Usmani, Saad, Richardson, Paul G., Plesner, Torben, Liu, Kevin, Orlowski, Robert Z., Losic, Nedjad, Jansson, Richard, Ahmadi, Tahamtan, Lantz, Kristen, Ruixo, Juan Jose Perez, Zhou, Honghui, Xu, Xu Steven
Publicado 2017

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

por Sonneveld, Pieter, Chanan-Khan, Asher, Weisel, Katja, Nooka, Ajay K., Masszi, Tamas, Beksac, Meral, Spicka, Ivan, Hungria, Vania, Munder, Markus, Mateos, Maria-Victoria, Mark, Tomer M., Levin, Mark-David, Ahmadi, Tahamtan, Qin, Xiang, Garvin Mayo, Wendy, Gai, Xue, Carey, Jodi, Carson, Robin, Spencer, Andrew
Publicado 2023

An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation

por Muik, Alexander, Altintas, Isil, Gieseke, Friederike, Schoedel, Kristina B, Burm, Saskia M, Toker, Aras, Salcedo, Theodora W., Verzijl, Dennis, Eisel, David, Grunwitz, Christian, Kranz, Lena M, Vormehr, Mathias, Satijn, David P.E., Diken, Mustafa, Kreiter, Sebastian, Sasser, Kate, Ahmadi, Tahamtan, Türeci, Özlem, Breij, Esther C.W., Jure-Kunkel, Maria, Sahin, Ugur
Publicado 2022

Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial

por Dimopoulos, Meletios A., Oriol, Albert, Nahi, Hareth, San-Miguel, Jesus, Bahlis, Nizar J., Usmani, Saad Z., Rabin, Neil, Orlowski, Robert Z., Suzuki, Kenshi, Plesner, Torben, Yoon, Sung-Soo, Ben Yehuda, Dina, Richardson, Paul G., Goldschmidt, Hartmut, Reece, Donna, Ahmadi, Tahamtan, Qin, Xiang, Garvin Mayo, Wendy, Gai, Xue, Carey, Jodi, Carson, Robin, Moreau, Philippe
Publicado 2023

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

por Thieblemont, Catherine, Phillips, Tycel, Ghesquieres, Herve, Cheah, Chan Y., Clausen, Michael Roost, Cunningham, David, Do, Young Rok, Feldman, Tatyana, Gasiorowski, Robin, Jurczak, Wojciech, Kim, Tae Min, Lewis, David John, van der Poel, Marjolein, Poon, Michelle Limei, Cota Stirner, Mariana, Kilavuz, Nurgul, Chiu, Christopher, Chen, Menghui, Sacchi, Mariana, Elliott, Brian, Ahmadi, Tahamtan, Hutchings, Martin, Lugtenburg, Pieternella J.
Publicado 2023

DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity

por Muik, Alexander, Adams, Homer C, Gieseke, Friederike, Altintas, Isil, Schoedel, Kristina B, Blum, Jordan M, Sänger, Bianca, Burm, Saskia M, Stanganello, Eliana, Verzijl, Dennis, Spires, Vanessa M, Vascotto, Fulvia, Toker, Aras, Quinkhardt, Juliane, Fereshteh, Mark, Diken, Mustafa, Satijn, David P E, Kreiter, Sebastian, Ahmadi, Tahamtan, Breij, Esther C W, Türeci, Özlem, Sasser, Kate, Sahin, Ugur, Jure-Kunkel, Maria
Publicado 2022

Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity

por Hiemstra, Ida H., Santegoets, Kim C.M., Janmaat, Maarten L., De Goeij, Bart E.C.G., Ten Hagen, Wessel, van Dooremalen, Sanne, Boross, Peter, van den Brakel, Jeroen, Bosgra, Sieto, Andringa, Grietje, van Kessel-Welmers, Berris, Verzijl, Dennis, Hibbert, Richard G., Frerichs, Kristine A., Mutis, Tuna, van de Donk, Niels W.C.J., Ahmadi, Tahamtan, Satijn, David, Sasser, A. Kate, Breij, Esther C.W.
Publicado 2023

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

por Muik, Alexander, Garralda, Elena, Altintas, Isil, Gieseke, Friederike, Geva, Ravit, Ben-Ami, Eytan, Maurice-Dror, Corinne, Calvo, Emiliano, LoRusso, Patricia M., Alonso, Guzman, Rodriguez-Ruiz, Maria E., Schoedel, Kristina B., Blum, Jordan M., Sänger, Bianca, Salcedo, Theodora W., Burm, Saskia M., Stanganello, Eliana, Verzijl, Dennis, Vascotto, Fulvia, Sette, Angelica, Quinkhardt, Juliane, Plantinga, Theo S., Toker, Aras, van den Brink, Edward N., Fereshteh, Mark, Diken, Mustafa, Satijn, David, Kreiter, Sebastian, Breij, Esther C.W., Bajaj, Gaurav, Lagkadinou, Eleni, Sasser, Kate, Türeci, Özlem, Forssmann, Ulf, Ahmadi, Tahamtan, Şahin, Uğur, Jure-Kunkel, Maria, Melero, Ignacio
Publicado 2022